- Microdose Psychedelic Insights will host the upcoming DMT Conference on September 9-10th, 2021
- Part of a series of deep dive events looking into various psychoactive and psychedelic substances, the DMT conference will examine the potential of DMT within today’s society
- The conference will play host to a number of keynote presentations and discussions delivered by some of the industry’s leading thinkers and innovators
Microdose Psychedelic Insights (“Microdose”) is set to host their virtual DMT Conference on September 9-10th, 2021. The event will serve as a deep dive into the dynamic field of DMT therapeutics, featuring a number of expert panels and engaging discussions focused on the potential of Dimethyltryptamine (“DMT”) in today’s society.
Microdose Psychedelic Insights, a cutting-edge media company focused around promoting content, financial analysis, and engaging events focused around the psychedelics industry, have gained renown for their unique vision towards shifting the global perception around psychedelic medicine through a series of innovative events.
Forming part of Microdose’s Molecular Masterclasses conference series, which has previously featured events looking into Ketamine, MDMA, Ibogaine and Functional Mushrooms, the DMT Conference will seek to introduce investors and attendees to a curated group of CEO’s, corporate leaders and scientists who will seek to delve deeper into the intricacies surrounding the DMT universe. This year’s conference will be inaugurated by an introductory talk, delivered by Patrick Moher, CEO of Microdose Psychedelic Insights. The conference will subsequently play host to a series of hour long presentations and keynote addresses exploring different aspects within the psychedelic industry and DMT in particular.
Topics which will be covered will include, “Addiction and DMT” delivered by Entheon Biomedical; “Non-Neuropsychiatric Uses for DMT” by PharmaDrug Inc, “DMT Drug Development” from Small Pharma INC; and a keynote presentation by Algernon Pharmaceuticals entitled “DMT – New Hope for Healing the Brain After a Stroke” among various others. In addition, the conference will also feature several other expert speakers, including the likes of Christopher Timmermann-Slater, Andrew Hegle, Paul Van Slyke, Daniel Cohen, Christopher Moreau, Jackie von Salm, Carol Routledge, Brian Jahns, Natan Ponieman, Andrew Hegle Paul Van Slyke, Christopher Timmermann-Slater Peter Rands, Graham Pechenik David Wood, Ruth Chun, Hadas Alterman Rick Strassman MD, Timothy Ko, Brian Jahns, Crystal Carson, Joël Brierre, Max Montrose, Tricia Eastman, Rak Razam, Victoria Wueschner.
Microdose’s DMT Conference will be presented in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Small Pharma (TSX.V: DMT) a neuropharmaceutical company taking a novel approach to depression drug development, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (“IPF”) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines.
Additional information about the DMT Conference, as well as details for registration can be found at the DMT Conference website at https://microdose.buzz/pnwmm
About Microdose Psychedelic Insights:
Microdose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, we distribute and create the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine.
About Molecular Masterclasses:
Our Molecular Masterclasses are a speaker series designed for deep dives into the world’s favourite psychoactive and psychedelic substances. Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world.
Contact:
Microdose Psychedelic Insights
kristina@microdose.buzz
Media Contact:
InvestorBrandNetwork (“IBN”)
Los Angeles, California
www.InvestorBrandNetwork.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
No comments:
Post a Comment